Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6482 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD6482 on top of ASA |
| 2 | ACTIVE_COMPARATOR | Clopidogrel on top of ASA |
| Name | Type | Description |
|---|---|---|
| AZD6482 | DRUG | Single intravenous infusion during a maximum of 5 hours |
| Clopidogrel | DRUG | Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7. |
| ASA | DRUG | 75 mg orally once daily during 7 days in each treatment arm |
| Placebo | DRUG | - |
Inclusion Criteria: * BMI between 19.0 and 30.0 kg/m2, inclusive and body weight between 50.0 and 100.0 kg, inclusive * Provision of written informed consent Exclusion Criteria: * Personal or family history of bleeding disorders, or reasonable suspicion of vascular malformations, including aneury...
AZD6482 is an investigational small molecule developed by AstraZeneca PLC for antiplatelet effect. It is a PI3K inhibitor that has been studied in Phase 1 clinical trials in healthy male volunteers. It is not approved for any indication and remains in clinical development.
AZD6482 targets phosphoinositide 3-kinase (PI3K) subunits, specifically PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2, and PIK3CD. It acts as an inhibitor of these targets. This mechanism is being explored for its antiplatelet effect, which relates to how platelets activate and aggregate.
AZD6482 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical trials investigating this compound. No other developer or partner is identified for this asset.
AZD6482 is in Phase 1 clinical development. Both of its recorded trials are Phase 1 studies and both are completed. There are no active trials. The drug is investigational and has not been approved by the FDA or any other regulatory agency for any indication.
AZD6482 has been studied in two completed Phase 1 trials: NCT00853450, a bleeding time study with AZD6482, clopidogrel and ASA conducted in Sweden with 28 participants, and NCT00688714, a safety and tolerability study of a single dose of AZD6482 with 49 participants. Both enrolled healthy male volunteers.
AZD6482 has been studied for antiplatelet effect in Phase 1 trials. The trials evaluated bleeding time and the safety and tolerability of a single dose in healthy male volunteers. It is an investigational agent and is not approved for any therapeutic use.